Publications by authors named "Abhya Gupta"

Claim this Profile
C
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.
James D Chalmers, Michal Shteinberg, Marcus A Mall, Anne E O'Donnell, Henrik Watz, Abhya Gupta

Eur Respir J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic characterization of the human segmental endotoxin challenge model.
Christina Gress, Tobias Litzenburger, Ramona Schmid, Ke Xiao, Florian Heissig, Abhya Gupta

Sci Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.
James D Crapo, Abhya Gupta, David A Lynch, Alice M Turner, Robert M Mroz

Respir Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.
Christina Gress, Jens Vogel-Claussen, Philipp Badorrek, Meike Müller, Kathrin Hohl, Abhya Gupta

Pulm Pharmacol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.
Lorraine B Ware, Nima Soleymanlou, Danny Francis McAuley, Vicente Estrada, George A Diaz, Abhya Gupta

Thorax· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.
James D Chalmers, Abhya Gupta, Sanjay H Chotirmall, April Armstrong, Peter Eickholz

ERJ Open Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP).
Ilaria Campo, Federica Meloni, Martina Gahlemann, Wiebke Sauter, Carina Ittrich, Abhya Gupta

Sci Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
Christopher H Goss, Isabelle Fajac, Raksha Jain, Wolfgang Seibold, Abhya Gupta

Eur Respir J· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD.
James Crapo, Abhya Gupta, David A Lynch, Jens Vogel-Claussen, Henrik Watz

BMJ Open· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis.
Peter Nickolaus, Birgit Jung, Juan Sabater, Samuel Constant, Abhya Gupta

ERJ Open Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF 1.
Christopher H Goss, Raksha Jain, Wolfgang Seibold, Anne-Caroline Picard, Ming-Chi Hsu, Abhya Gupta

ERJ Open Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FEV recovery following methacholine challenge in asthma: Variability and comparison of methods.
Dave Singh, Naimat Khan, James Dean, Andrew Fowler, Abhya Gupta

Pulm Pharmacol Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.
Katherine E Lowe, Elizabeth A Regan, Antonio Anzueto, Erin Austin, John H M Austin, Abhya Gupta

Chronic Obstr Pulm Dis· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Andy Fowler, Rüdiger Koenen, James Hilbert, Jon Blatchford, Dominik Kappeler, Abhya Gupta

J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
David Miller, Chester Wood, Eric Bateman, Craig LaForce, Jon Blatchford, Abhya Gupta

Allergy Asthma Proc· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.
Ian P Hall, Andrew V Fowler, Abhya Gupta, Kay Tetzlaff, Michael C Nivens

Pulm Pharmacol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.
Norbert Krug, Abhya Gupta, Philipp Badorrek, Ruediger Koenen, Meike Mueller

J Allergy Clin Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Abhya Gupta

N Engl J Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia.
Bernt van den Blink, Judith Branger, Sebastiaan Weijer, Abhya Gupta, Sander J H van Deventer

J Clin Immunol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.
Judith Branger, Bernt van den Blink, Sebastiaan Weijer, Abhya Gupta, Sander J H van Deventer

Blood· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.
Judith Branger, Bernt van den Blink, Sebastiaan Weijer, Jeffrey Madwed, Carina L Bos, Abhya Gupta

J Immunol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis